Marine-Derived Drugs in Alzheimer's: Modest, Inconsistent Cognitive Signals

This Bayesian network meta-analysis quantifies the comparative cognitive efficacy and short-term safety of five marine-derived agents in Alzheimer's disease, informing how pharmacists interpret emerging naturally sourced therapeutics against a backdrop of largely negative confirmatory data.

GV-971sodium oligomannatetramiprosatehomotaurineomega-3 fatty acidsbryostatin-1rifampicindoxycyclineAlzheimer's diseasenetwork meta-analysiscognitive outcomesmarine-derived drugs Neurology / Neuropharmacology

Background Information

Marine-derived drugs show potential but varied cognitive effects in Alzheimer's.

Marine-derived drugs are being explored for cognitive benefits in Alzheimer's disease (AD), but comparative efficacy and safety require clarification. GV-971 improved ADAS-Cog scores (MD -1.85, 95% CI -2.89 to -0.82), and rifampicin showed potential MMSE benefits (MD 1.90, 95% CI 0.25 to 3.56), but outcomes varied. While some marine drugs show cognitive improvement in specific measures, none are consistently superior; further large RCTs are needed to determine optimal treatments. Marine-derived drugs show potential but inconsistent cognitive benefits in Alzheimer's disease.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Song Z, Xie Y, Zhu H, Li J, Yang C, Guo Y, Nong X, Zhu Z, Chen Z, Wang Z

Citation: Song Z, Xie Y, Zhu H, et al. Evaluating the cognitive efficacy of marine-derived drugs in Alzheimer's disease: A systematic review and Bayesian network meta-analysis. Therapeutic advances in neurological disorders. 2026;19:17562864261476868. doi:10.1177/17562864261476868

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →